Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

European Journal of Immunology

Volumn 47, Issue 2, 2017, Pages 385-393

  van Hooren, Luuk ^a   Sandin, Linda C ^a   Moskalev, Igor ^b   Ellmark, Peter ^c,d   Dimberg, Anna ^a   Black, Peter ^c   Tötterman, Thomas H ^a   Mangsbo, Sara M ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Alligator Bioscience AB   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Bladder cancer; Checkpoint inhibitors; CTLA 4; Immunotherapy; Local low dose; MB49; PD 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INTERLEUKIN 6; ANTINEOPLASTIC AGENT; CYTOKINE; GROWTH INHIBITOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CYTOKINE RELEASE; CYTOKINE RESPONSE; FEMALE; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SYSTEMIC THERAPY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; COMBINATION DRUG THERAPY; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; METABOLISM; PROCEDURES; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CTLA-4 ANTIGEN; CYTOKINES; DRUG THERAPY, COMBINATION; GROWTH INHIBITORS; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; URINARY BLADDER NEOPLASMS;

EID: 85006725021     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201646583     Document Type: Article

References (31)

1. Schwartz, R. H., Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992. 71: 1065–1068.
2. Quezada, S. A., Peggs, K. S., Curran, M. A. and Allison, J. P., CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006. 116: 1935–1945.
3. Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T. et al., Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 2007. 13: 2158–2167.
4. Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C. et al., Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013. 210: 1695–1710.
5. Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R. et al., Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 2013. 123: 2447–2463.
6. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R. et al., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010. 363: 711–723.
7. Cameron, F., Whiteside, G. and Perry, C., Ipilimumab: first global approval. Drugs 2011. 71: 1093–1104.
8. Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D. et al., Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 2015. 33: 1889–1894.
9. Schumacher, T. N. and Schreiber, R. D., Neoantigens in cancer immunotherapy. Science 2015. 348: 69–74.
10. Redelman-Sidi, G., Glickman, M. S. and Bochner, B. H., The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat. Rev. Urol. 2014. 11: 153–162.
11. Fayos, J. V. and Morales, P. H., Carcinoma of the endometrium results of treatment. Int. J. Radiat. Oncol. Biol. Phys. 1980. 6: 571–576.
12. Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J. et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014. 515: 558–562.
13. Postow, M. A., Callahan, M. K. and Wolchok, J. D., Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 2015. 33: 1974–1982.
14. Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B. and Postow, M. A., Opportunistic infections in patients treated with immunotherapy for cancer. J. Immunother. Cancer 2014. 2: 19.
15. Buchbinder, E. I. and Desai, A., CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 2015. 39: 98–106.
16. Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A. S., Totterman, T. H. and Mangsbo, S. M., Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology 2014. 3: e27614.
17. Fransen, M. F., van der Sluis, T. C., Ossendorp, F., Arens, R. and Melief, C. J., Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res. 2013. 19: 5381–5389.
18. Rahimian, S., Fransen, M. F., Kleinovink, J. W., Amidi, M., Ossendorp, F. and Hennink, W. E., Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. Biomaterials 2015. 61: 33–40.
19. Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G. et al., Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 2010. 16: 2861–2871.
20. Duthie, J. B., Vincent, M., Herbison, G. P., Wilson, D. I. and Wilson, D., Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst. Rev. 2011: CD005493.
21. Sandin, L. C., Orlova, A., Gustafsson, E., Ellmark, P., Tolmachev, V., Totterman, T. H. and Mangsbo, S. M., Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol. Res. 2014. 2: 80–90.
22. Hafalla, J. C., Claser, C., Couper, K. N., Grau, G. E., Renia, L., de Souza, J. B. and Riley, E. M., The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Pathog. 2012. 8: e1002504.
23. Fransen, M. F., Sluijter, M., Morreau, H., Arens, R. and Melief, C. J., Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin. Cancer Res. 2011. 17: 2270–2280.
24. Mangsbo, S. M., Ninalga, C., Essand, M., Loskog, A. and Totterman, T. H., CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J. Immunother. 2008. 31: 34–42.
25. Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A. and Totterman, T. H., Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother. 2010. 33: 225–235.
26. Malmstrom, P. U., Loskog, A. S., Lindqvist, C. A., Mangsbo, S. M., Fransson, M., Wanders, A., Gardmark, T. et al., AdCD40L immunogene therapy for bladder carcinoma—the first phase I/IIa trial. Clin. Cancer Res. 2010. 16: 3279–3287.
27. Jager, W., Moskalev, I., Janssen, C., Hayashi, T., Awrey, S., Gust, K. M., So, A. I. et al., Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. PLoS One 2013. 8: e59536.
28. Gajewski, T. F., Schreiber, H. and Fu, Y. X., Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013. 14: 1014–1022.
29. Becht, E., Giraldo, N. A., Dieu-Nosjean, M. C., Sautes-Fridman, C. and Fridman, W. H., Cancer immune contexture and immunotherapy. Curr. Opin. Immunol. 2016. 39: 7–13.
30. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D. et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015. 373: 23–34.
31. Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R. et al., Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016. 17: 299–308.